News | Cardiovascular Clinical Studies | July 15, 2022

Molecular Heart Mapping and Cripsr Technology Create New Possibilities for Health Science

MMRI Scientist Dr. Nathan Tucker co-authors groundbreaking study with team from The Broad Institute of MIT and Harvard, Bayer AG
 

MMRI Scientist Dr. Nathan Tucker co-authors groundbreaking study with team from The Broad Institute of MIT and Harvard, Bayer AG

Image courtesy of MMRI


July 15, 2022 — Imagine, if scientists had a map of the heart, so granular in its accuracy that it even profiled details of the heart at the cellular level. What if we could zoom in even further, via single nucleus profiling, to peer inside the heart with a molecular view? Imagine the incredible possibilities of such a detailed map: With this knowledge, doctors will be better able to diagnose and treat diseases of the heart and cardiovascular system.    

This is precisely what a team of 19 scientists are determined to learn, in a new peer-reviewed study published in the science journal, Nature. The study, titled, “Single-nucleus profiling of human dilated and hypertrophic cardiomyopathy,” identified molecular alterations in failing hearts at single-cell resolution, by performing single-nucleus RNA sequencing of nearly 600,000 nuclei. This is truly a story of how a “small view” can have “big possibilities.”   

The team was led by Patrick T. Ellinor, MD, PhD an Institute Member at the Broad Institute of MIT and Harvard and a cardiologist in the Demoulas Center for Cardiac Arrhythmias at the Massachusetts General Hospital Heart Center. Dr. Ellinor’s team included scientists from the Precision Cardiology Lab (PCL) of the Broad Institute of MIT and Harvard and Bayer, AG and MMRI.    

Dr. Nathan Tucker of Masonic Medical Research Institute was a driving force behind the initiation of the study when he was at Broad, and he continued to contribute to the study from his lab in Utica, New York. “We often think of hearts solely as muscles, but they are actually a complex mixture of cells that need to work together in order to perform its function as a pump,” said Dr. Tucker, regarding the new study. “In the past, we have not been able to look at these other critical components, but through revolutionary technology such as we use here, our ability to accurately examine these other cells is unlocked. In this study, using this technology and a series of human tissue samples, we identified novel state transitions in end stage heart failure at single cell resolution. It is our hope to use these new targets as the basis for therapeutic development in the future.”  

The ground-breaking effort builds upon Dr. Tucker’s already extensive work on heart mapping. In 2020, Dr. Tucker led a team to create a cell map of the human heart, the most comprehensive to date, stating, “Understanding of human cardiac biology at this resolution was not possible just a few years ago."  

For more information: www.MMRI.edu 


Related Content

Feature | Heart Failure | Kyle Hardner

Editor's Note: This is Part Three of a three-part series highlighting several of the presentations from the American ...

Home May 13, 2026
Home
News | Heart Failure

May 10, 2026 — Results from the first randomized trial evaluating microRNA inhibition in heart failure were presented ...

Home May 11, 2026
Home
Feature | Heart Failure | Kyle Hardner

Could a link between the heart, brain and immune system help reduce the occurrence of heart attacks and lessen the ...

Home May 04, 2026
Home
News | Heart Failure

April 21, 2026 — Nuwellis, Inc. has announced a software update to its Aquadex SmartFlow ultrafiltration platform. The ...

Home April 23, 2026
Home
News | Heart Failure

March 28, 2026 — Amgen announced today that Repatha (evolocumab), when added to statins or other low-density lipoprotein ...

Home April 06, 2026
Home
News | Heart Failure

March 24, 2026 — New research shows that small improvements to sleep, diet quality and physical activity, made in ...

Home March 25, 2026
Home
News | Heart Failure

March 16, 2026 — Cytokinetics has announced four presentations related to Myqorzo (aficamten) at the American College of ...

Home March 16, 2026
Home
Feature | Heart Failure | Rohit Sood, MD, PhD

Cardiovascular disease (CVD) is a serious global health burden that encompasses a broad group of diseases that affect ...

Home February 12, 2026
Home
News | Heart Failure

Feb. 3, 2026 — Bristol Myers Squibb has launched "Change the Target. Change What’s Possible," an educational campaign ...

Home February 03, 2026
Home
News | Heart Failure

Jan. 27, 2026 — A new national study reveals a stark disconnect between Americans’ desire for preventive cardiac ...

Home January 27, 2026
Home
Subscribe Now